findmyKOL
Clinical trialNCT02291913CompletedPhase 2Interventional

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

SponsorSCRI Development Innovations, LLCEnrollment48Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Many patients with ER-positive or PR-positive breast cancer are treated with endocrine therapy. Although most ER/PR-positive tumors initially respond to hormonal therapy, patients often experience disease progression. Everolimus, in combination with exemestane, has shown activity in endocrine-resistant disease. This study will evaluate the efficacy of Everolimus+ anti-estrogen therapy in patients with ER-positive metastatic breast cancer who have progressed after receiving anti-estrogen therapy.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Florida Cancer Specialists-South

    Fort Myers, Florida, United States

  • Memorial Cancer Center

    Hollywood, Florida, United States

  • Woodlands Medical Specialists

    Pensacola, Florida, United States

  • Florida Cancer Specialists-East

    West Palm Beach, Florida, United States

  • Hope Cancer Center

    Terre Haute, Indiana, United States

  • Tennessee Oncology

    Chattanooga, Tennessee, United States

  • Tennessee Oncology Pllc

    Nashville, Tennessee, United States

  • Center for Cancer and Blood Disorders

    Fort Worth, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Anastrozole →Everolimus →Exemestane →Fulvestrant →Letrozole →Tamoxifen →Toremifine
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
18 Dec 2014
Primary completion
31 Jan 2019
Completion
31 Jan 2019
Last update posted
17 Feb 2020
Registered enrollment
48
Registry id
NCT02291913
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.